Literature DB >> 16439743

Ibutilide for treatment of atrial fibrillation in the emergency department.

O Viktorsdottir1, A Henriksdottir, D O Arnar.   

Abstract

The purpose of this study was to assess the efficacy and safety of ibutilide, a class III antiarrhythmic drug, for acute treatment of atrial fibrillation (AF) in the emergency department (ED) setting. A retrospective analysis was done reviewing all patients with AF who received ibutilide in the ED in a university hospital setting. A total of 22 patients received ibutilide. Another 24 patients who received rate control drugs only served as a control group. Of the 22 patients who received ibutilide, 14 (64%) converted to sinus rhythm. The mean (SD) rate of AF was 137 (24) bpm and the mean QTc interval immediately after conversion to sinus rhythm was 420 (28) ms. There were no complications. In the rate control group 7 patients (29%) converted to sinus rhythm (p<0.05, compared with ibutilide). The mean rate of AF was 126 (26) bpm (p = ns, compared with ibutilide) and the mean QTc interval in those who converted was 377 (28) ms (p<0.05, compared with ibutilide). One patient developed severe bradycardia. Ibutilide is effective for conversion of recent onset AF in patients presenting to the ED and there is a low rate of complications from ibutilide in this setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439743      PMCID: PMC2564036          DOI: 10.1136/emj.2004.021394

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  8 in total

Review 1.  Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography.

Authors:  Robert L McNamara; Leonardo J Tamariz; Jodi B Segal; Eric B Bass
Journal:  Ann Intern Med       Date:  2003-12-16       Impact factor: 25.391

2.  Synchronized emergency department cardioversion of atrial dysrhythmias saves time, money and resources.

Authors:  Jeanne L Jacoby; Mark Cesta; Michael B Heller; Philip Salen; James Reed
Journal:  J Emerg Med       Date:  2005-01       Impact factor: 1.484

3.  Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.

Authors:  B S Stambler; M A Wood; K A Ellenbogen
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

4.  Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.

Authors:  M A Vos; S R Golitsyn; K Stangl; M Y Ruda; L V Van Wijk; J D Harry; K T Perry; P Touboul; G Steinbeck; H J Wellens
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

5.  Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.

Authors:  B S Stambler; M A Wood; K A Ellenbogen; K T Perry; L K Wakefield; J T VanderLugt
Journal:  Circulation       Date:  1996-10-01       Impact factor: 29.690

Review 6.  Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation.

Authors:  Ijaz A Khan
Journal:  Int J Cardiol       Date:  2003-02       Impact factor: 4.164

7.  Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset.

Authors:  Johann Reisinger; Edmund Gatterer; Wolfgang Lang; Thetis Vanicek; Geza Eisserer; Theresia Bachleitner; Christopher Niemeth; Friedrich Aicher; Wilhelm Grander; Georg Heinze; Peter Kühn; Peter Siostrzonek
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

8.  Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings.

Authors:  E H Locati; P Maison-Blanche; P Dejode; B Cauchemez; P Coumel
Journal:  J Am Coll Cardiol       Date:  1995-06       Impact factor: 24.094

  8 in total
  4 in total

1.  Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation.

Authors:  I Vogiatzis; E Papavasiliou; I Dapcevitch; S Pittas; E Koulouris
Journal:  Hippokratia       Date:  2017 Apr-Jun       Impact factor: 0.471

Review 2.  Management and Disposition of Atrial Fibrillation in the Emergency Department: A Systematic Review.

Authors:  Justin L Vandermolen; Murrium I Sadaf; Anil K Gehi
Journal:  J Atr Fibrillation       Date:  2018-06-30

3.  Body Weight Counts-Cardioversion with Vernakalant or Ibutilide at the Emergency Department.

Authors:  Teresa Lindmayr; Sebastian Schnaubelt; Patrick Sulzgruber; Alexander Simon; Jan Niederdoeckl; Filippo Cacioppo; Nikola Schuetz; Hans Domanovits; Alexander Oskar Spiel
Journal:  J Clin Med       Date:  2022-08-28       Impact factor: 4.964

4.  Ibutilide with magnesium for conversion of atrial fibrillation or flutter in rheumatic heart disease patients: Ibutilide with magnesium for chemical cardioversion of atrial fibrillation or flutter.

Authors:  Amit Malviya; Manish Kapoor; Rondeep Kumar Nath Sivam; Shakeel Ahamad Khan; Ruchi Pandey; Utpal Kumar; Tony Ete; Animesh Mishra
Journal:  Indian Heart J       Date:  2020-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.